What is Marker Therapeutics Profitability Rank?
Marker Therapeutics has the Profitability Rank of 0.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Marker Therapeutics's Operating Margin % for the quarter that ended in Sep. 2024 was %. As of today, Marker Therapeutics's Piotroski F-Score is 2.
Competitive Comparison of Marker Therapeutics's Profitability Rank
For the Biotechnology subindustry, Marker Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marker Therapeutics's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Marker Therapeutics's Profitability Rank falls into.
Marker Therapeutics Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.
Marker Therapeutics has the Profitability Rank of 0.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Marker Therapeutics's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Marker Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Marker Therapeutics Business Description
Traded in Other Exchanges
Address
9350 Kirby Drive, Suite 300, Houston, TX, USA, 77054
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.
Executives
| New Enterprise Associates 16, L.p. |
10 percent owner |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Steve Elms |
director |
888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106 |
| Eliot M Lurier |
officer: Interim CFO |
C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
| Katharine Knobil |
director |
C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421 |
| Frederick Gerald Wasserman |
director |
4 NOBADEER DRIVE, PENNINGTON NJ 08534 |
| Peter W. Sonsini |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Peter L. Hoang |
director, officer: CEO and President |
C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
| Paul Edward Walker |
director |
1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
| Mohamad Makhzoumi |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Carmen Chang |
10 percent owner |
2855 SAND HILL ROAD, MENLO PARK CA 94025 |
| Ali Behbahani |
director |
5425 WISCONSIN AVE, CHEVY CHASE MD 20815 |
| Florence Anthony A. Jr. |
10 percent owner |
5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815 |
| Norman David Eansor |
director |
8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120 |
| Forest Baskett |
10 percent owner |
|
| Joshua Makower |
10 percent owner |
1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRKR has been successfully added to your